Supporting Anaveon in Transitioning to Early Clinical Development
Summary
Anaveon, a clinical-stage biotech backed by €140M+ in funding, was preparing to advance its lead immunotherapy asset into its first-in-human (FIH) trial.
Despite a strong scientific foundation, recent Series A success, and a senior internal team, they lacked operational capacity and had minimal experience in running CRO selection.
With timelines tightening and strategic visibility increasing, the stakes were high: the right outsourcing decisions could set the tone for their clinical and investor trajectories.
This is a doorway to many different things if we get this right...and we needed to get it right the first time.
They took us from a certain point to another, like a bridge for us to cross that river.
CRO’s evaluated
Budget Reduced during CRO contract negotiations
timelines achieved
What Seuss+ Delivered
Structured CRO Selection Aligned to Strategic Objectives
Through our Vendor Relationship Maximization Method (VRMM), we translated Anaveon’s strategic needs into a fit-for-purpose CRO selection framework that supported informed decisions and long-term alignment. Our role was not just advisory; we embedded with Anaveon’s team to co-ordinate, deliver, and drive each critical step. We also handled all communication with the CRO’s and led the contract negotiations on Anaveon’s behalf, ensuring a fair agreement that drives sponsor-vendor collaboration and accountability. Anaveon entered Phase ½ with confidence that they had a best-fit CRO partner to drive the clinical development success of their asset.
The Risk/Challenge
Transitioning from preclinical to clinical development with no margin for error
Senior leaders with big pharma experience, but limited CRO selection familiarity
Need to instill confidence across stakeholders, including the board, in both process and partner
Critical to preserve decision-making momentum and mitigate risk early
The Results
CRO partner was selected that matched Anaveon’s scientific, operational, and cultural criteria
Process clarity and board confidence established early, enabling swift governance buy-in
Compliance built in: full documentation supported, 100% regulatory alignment
Series B readiness achieved: first patient dosed within timelines; subsequent financing closed
Anaveon entered Phase 2 with both their asset and team prepared to lead
Successful contract negotiations
How We Helped
Defined vendor selection strategy anchored in both technical criteria and team culture fit
Scoped and shortlisted CROs through structured profiling, financial review, and qualification
Orchestrated bid defense meetings, translating complex data into clear decision points
Maintained alignment with key stakeholders, including board members, throughout the process
Led negotiations of the MSA, SUA, and Work Order with the CRO on behalf of Anaveon freeing up their internal capacity to focus on execution
Frequently asked questions
Standing up the vendor strategy, selection, and operational infrastructure a company needs for its first clinical trial, before execution starts.
We built the vendor strategy and the operational base for early clinical development, so the transition was structured rather than reactive.
Because the choices made before the first trial set the trajectory. Getting vendor strategy and infrastructure right upstream avoids rework later.
Other Related Case Studies
Schedule a consultation now
Key takeaways
- The challenge: moving from preclinical into a first clinical trial, where the operational base has to be built from scratch.
- Seuss+ set the vendor strategy and infrastructure for early clinical development.
- The work shaped readiness before the trial scaled.
Talk to the Seuss+ team
Book a 30-minute strategic call to see how this fits your trial.
Book an intro call